Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered into a strategic partnership with SPH RD, a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd focused on rare diseases and pediatrics. The collaboration centers around BDgene’s innovative BDlendi insulator technology, which is slated for the advancement of SPH RD’s hemophilia treatment products. The financial terms of the agreement include an undisclosed upfront payment, milestone payments, and royalties.
BDgene’s BDlenti platform is a next-generation lentiviral vector engineered to enhance the safety of lentiviral vectors through the integration of micro insulator components, without compromising the carrier’s titer. Lentiviral vectors play a pivotal role in the treatment of rare hematopoietic system diseases, CAR-T cell therapy, and in vivo gene therapy. The adoption of BDlent insulator technology is expected to contribute to the development of safer cell and gene therapies. Notably, BDgene’s gene therapy product BD211 for thalassemia has already been developed utilizing the BDlenti technology platform.- Flcube.com
